Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.

Analysts Target

Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield	Industry
1299	HK$72.65	-0.8%	4.3%	HK$751.7b	HK$103.83	15.4	12.9%	2.7%	Insurance
9999	HK$206.80	0.7%	2.5%	HK$662.5b	HK$250.01	16.8	9.8%	2.2%	Media
2388	HK$45.34	4.9%	23.2%	HK$479.4b	HK$48.32	1.3	5.1%	4.7%	Banks
9633	HK$39.74	-4.6%	1.6%	HK$446.9b	HK$55.22	24.4	10.9%	2.9%	Food, Beverage & Tobacco
1816	HK$2.75	1.9%	-0.7%	HK$205.8b	HK$3.64	12.7	9.1%	3.6%	Utilities
3692	HK$31.94	-5.2%	1.4%	HK$193.7b	HK$46.68	30.1	10.8%	1.3%	Pharmaceuticals & Biotech
3908	HK$21.58	-3.5%	12.9%	HK$163.0b	HK$28.87	8.5	16.4%	2.5%	Diversified Financials
1801	HK$89.70	2.2%	11.4%	HK$155.9b	HK$116.77	165.7	31.6%	n/a	Pharmaceuticals & Biotech
358	HK$31.22	-1.6%	103.3%	HK$145.4b	HK$46.59	11.7	11.8%	4.4%	Materials
688	HK$12.91	3.1%	-6.2%	HK$141.3b	HK$17.90	9.6	9.6%	3.9%	Real Estate Management and Development
27	HK$31.48	4.3%	-18.4%	HK$137.7b	HK$46.38	12.9	7.1%	5.1%	Consumer Services
6881	HK$7.25	-4.5%	-24.6%	HK$134.8b	HK$11.24	5.9	11.6%	5.6%	Diversified Financials
2333	HK$8.64	-2.4%	-32.4%	HK$129.7b	HK$16.48	7.1	11.1%	4.7%	Automobiles
3	HK$6.63	1.7%	-1.2%	HK$123.7b	HK$7.34	21.7	4.6%	5.3%	Utilities
6990	HK$516.50	3.5%	51.9%	HK$120.4b	HK$547.64	50.6	44.8%	n/a	Pharmaceuticals & Biotech
1929	HK$11.60	0.3%	-15.9%	HK$114.4b	HK$15.67	12.7	9.6%	5.8%	Retail
1928	HK$13.34	-1.3%	-30.6%	HK$108.0b	HK$21.33	15.4	14.1%	5.6%	Consumer Services
1138 New	HK$13.08	-10.1%	93.8%	HK$92.9b	HK$23.61	11.2	20.7%	3.4%	Energy
1308	HK$33.52	-0.4%	42.3%	HK$90.9b	HK$35.22	9.5	-5.4%	9.1%	Transportation
6823	HK$11.95	0.3%	-3.0%	HK$90.6b	HK$13.70	17.1	5.2%	6.8%	Telecom
9926	HK$97.25	-5.0%	-14.1%	HK$89.6b	HK$171.75	25.3	46.8%	n/a	Pharmaceuticals & Biotech
1209 New	HK$37.86	-1.9%	0.4%	HK$86.4b	HK$53.54	18.8	10.9%	5.3%	Real Estate Management and Development
1768	HK$368.20	1.7%	n/a	HK$80.2b	HK$508.87	29.8	24.7%	n/a	Consumer Retailing
2268	HK$60.30	-2.3%	31.1%	HK$76.1b	HK$83.43	44.5	29.2%	n/a	Pharmaceuticals & Biotech

Undervalued over 20% based on DCF